Genfit climbs 3% following an update of its financial outlook, due to the validation of submissions for approval of elafibranor in Primary Biliary Cholangitis by the US FDA and the European Medicines.
Our November 2023 hepatology month in review spotlights data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) as well as news about hepatitis B and C.